Paper Details

  1. Home
  2. Paper Details

A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.

Author: , ErikssonMats, JohnsonOwe, KjellströmThomas, LankeJan, LarsenMogens Lytken, OlssonAnders G, PedersenTerje, TikkanenMatti J, WiklundOlov

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Atorvastatin is more effective than simvastatin in reducing LDL-C and TG levels and at achieving recommended lipid targets in patients with cardiovascular disease and dyslipidemia. Both statins are well tolerated.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Guidelines for the prevention of coronary heart disease call for low-density lipoprotein cholesterol (LDL-C) reduction as the primary target of treatment and reduction of triglycerides (TG) as an additional target. OBJECTIVE: The purpose of this study was to investigate the ability of a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0149-2918(03)90015-4

データ提供：米国国立医学図書館（NLM）

Statins: A Race to Reach Lipid Targets

This study compares the effectiveness of atorvastatin and simvastatin in reducing LDL-C and triglycerides (TG) levels in patients with cardiovascular disease and dyslipidemia. Dyslipidemia is a condition characterized by abnormal lipid levels in the blood, increasing the risk of heart disease. The study aimed to determine which statin, a class of drugs that lower cholesterol levels, was more effective in reaching specific lipid targets.

Atorvastatin: Outperforming the Competition

The study found that atorvastatin was significantly more effective than simvastatin in reducing LDL-C and TG levels. Atorvastatin achieved greater reductions in both lipid levels and a higher percentage of patients reached the recommended LDL-C target. This suggests that atorvastatin may be a more potent option for managing dyslipidemia in this patient population. It's like having a faster camel in the race to reach the lipid targets.

Well-Tolerated Treatment: A Safe and Effective Choice

Both atorvastatin and simvastatin were well tolerated in the study, with minimal side effects. This suggests that both statins can be safe and effective options for patients with cardiovascular disease and dyslipidemia. The study highlights the importance of choosing the right statin for each individual, considering factors such as lipid levels and potential side effects. It's important to consult with a healthcare professional to find the best treatment option for your specific needs.

Dr. Camel's Conclusion

This research provides valuable insights into the comparative effectiveness of atorvastatin and simvastatin in managing dyslipidemia. It emphasizes the importance of choosing the right statin for each patient, considering factors such as lipid levels, potential side effects, and individual preferences.

Date :
  1. Date Completed 2003-05-19
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

12637115

DOI: Digital Object Identifier

10.1016/s0149-2918(03)90015-4

Related Literature

Article Analysis
・Effective treatment of cholesterol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.